AI-generated analysis. Always verify with the original filing.
LeonaBio, Inc. filed an 8-K/A amending its prior disclosure on the Sermonix License Agreement for exclusive rights to lasofoxifene outside Sermonix's retained territory, adding the exhibit and updating company references.
This 8-K/A amendment fulfills SEC Staff conditions by incorporating the full Sermonix License Agreement as Exhibit 2.1, which grants LeonaBio exclusive rights to lasofoxifene—a selective estrogen-receptor modulator—for global development and commercialization outside Sermonix's retained territory. The transaction, originally disclosed December 18, 2025, now includes updated references from Athira Pharma to LeonaBio, reflecting a name change, alongside Sermonix Securities Issuance details in Exhibits 10.2, 4.5, and 4.4. Critically, it provides transparency on ELAINE-3, the ongoing Phase 3 trial (NCT05696626) for lasofoxifene in oncology. Sermonix's constrained spending totaled $31M across 2023-2025, but LeonaBio's enhanced resources enable accelerated execution: $11M spent post-close in 2025, with $45M and $30M projected for 2026-2027 on expanded CRO activities (fourfold increase), CMC, and personnel. Protocol changes boost sample size to 600 for sufficient progression events, targeting Q4 2026 enrollment and H2 2027 topline data. These updates signal LeonaBio's commitment to intensified development, differentiating from Sermonix's limitations and positioning lasofoxifene as a key pipeline asset amid forward-looking risks.
Event Type
Disclosure
Amendment
Variant
8-K/A
contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking stateme
Financial Statements and Exhibits. (d) Exhibits . | Exhibit No. | Description | |---|---| | 2.1* | License Agreement between Sermonix Pharmaceuticals, Inc. and
Material Agreement